Portal de Periódicos da CAPES

The Thymus–Neuroendocrine Axis

2009; Wiley; Volume: 1153; Issue: 1 Linguagem: Inglês

10.1111/j.1749-6632.2008.03964.x

1749-6632

Paula C. Reggiani, Gustavo R. Morel, Gloria M. Cónsole, Cláudio Gustavo Barbeito, Silvia Susana Rodríguez, Oscar A. Brown, María José Bellini, Jean‐Marie Pléau, Mireille Dardenne, Rodolfo G. Goya,

Antimicrobial Peptides and Activities

Thymulin is a thymic hormone exclusively produced by the thymic epithelial cells. It consists of a nonapeptide component coupled to the ion zinc, which confers biological activity to the molecule. After its discovery in the early 1970s, thymulin was characterized as a thymic hormone involved in several aspects of intrathymic and extrathymic T cell differentiation. Subsequently, it was demonstrated that thymulin production and secretion is strongly influenced by the neuroendocrine system. Conversely, a growing core of information, to be reviewed here, points to thymulin as a hypophysotropic peptide. In recent years, interest has arisen in the potential use of thymulin as a therapeutic agent. Thymulin was shown to possess anti-inflammatory and analgesic properties in the brain. Furthermore, an adenoviral vector harboring a synthetic gene for thymulin, stereotaxically injected in the rat brain, achieved a much longer expression than the adenovirally mediated expression in the brain of other genes, thus suggesting that an anti-inflammatory activity of thymulin prevents the immune system from destroying virus-transduced brain cells. Other studies suggest that thymulin gene therapy may also be a suitable therapeutic strategy to prevent some of the endocrine and metabolic alterations that typically appear in thymus-deficient animal models. The present article briefly reviews the literature on the physiology, molecular biology, and therapeutic potential of thymulin.